Cullinan Therapeutics, Inc. CGEM

Cullinan Therapeutics (NasdaqGS:CGEM) plans to report clinical data updates from three T cell engager programs in Q4 2026. The update will include new results for autoimmune and oncology candidates Velinotamig, CLN-978, and CLN-049. Cullinan also anticipates starting a Phase 2 study of CLN-049 after discussions with the US Food and Drug Administration. The planned Q4 2026 readouts and CLN-049 Phase 2 launch sit alongside a broader picture our research has uncovered. Take a look at 3 warning...

Additional multi-dose data for CLN-978 in difficult-to-treat rheumatoid arthritis (RA), once expected in the third quarter, will now arrive in December.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) plans to report clinical data from three T cell engager programmes during the fourth quarter of 2026, covering candidates being evaluated in autoimmune diseases and acute myeloid leukaemia.

Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren’s disease in December CLN-049 (FLT3 TCE) updated data from the Phase 1 dose escalation study in December CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in au

Cullinan Therapeutics stock moves after Phase 3 zipalertinib data Cullinan Therapeutics (CGEM) is back in focus after Phase 3 REZILIENT3 trial results showed zipalertinib plus chemotherapy improved progression free survival for EGFR exon 20 insertion non small cell lung cancer patients. Recent trading tells a mixed story for Cullinan Therapeutics. The share price has fallen about 22% over the past day and over the last month, and is down close to 9% over 90 days. However, the year to date...

Taiho Pharmaceutical, Taiho Oncology and Cullinan Therapeutics recently reported that the Phase 3 REZILIENT3 trial of investigational EGFR inhibitor zipalertinib plus chemotherapy in previously untreated EGFR exon 20 insertion-positive advanced non-small cell lung cancer met its primary endpoint, delivering a statistically significant 6.0‑month median progression‑free survival improvement over chemotherapy alone with no new safety signals identified. For Cullinan, these late‑breaking data...

Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names.

CAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, Septem

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) disclosed detailed Phase 3 REZILIENT3 results on September 13, 2026, in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Zipalertinib plus chemotherapy achieved median progression-free survival of 14.5 months, compared with 8.5 months for chemotherapy alone. Progression-free survival, or […]

Cullinan Therapeutics (NASDAQ:CGEM) shares fell 6. 3% on Monday after the company and its partners reported Phase 3 results for zipalertinib in patients with a form of non-small cell lung cancer.

Company to host a virtual event today at 8:00 a.m. ETCAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that it will host a virtual event for analysts and institutional investors today at 8:00 a.m. ET to discuss the results from the planned interim analysis of the Phase 3 REZIL

PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass., September 13, 2026--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial evaluating zipalertinib plus chemotherapy versus chemotherapy alone in the first-line treatment of patients with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutation-positive non-small cell lung cancer (NSCLC). The data were presented at the Internation

Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential Symposium 2 on Sunday, September 13, 2026 Company to host a virtual event on Monday, September 14, 2026, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class,

PRINCETON, N.J. & CAMBRIDGE, Mass., August 19, 2026--REZILIENT3 trial results have been selected for presentation in the Presidential Symposium 2 at the IASLC 2026 World Conference on Lung Cancer.